Recent advances in cardio‐oncology: a report from the ‘Heart Failure Association 2019 and World Congress on Acute Heart Failure 2019’

Clicks: 279
ID: 99969
2019
Abstract While anti‐cancer therapies, including chemotherapy, immunotherapy, radiotherapy, and targeted therapy, are constantly advancing, cardiovascular toxicity has become a major challenge for cardiologists and oncologists. This has led to an increasing demand of cardio‐oncology units in Europe and a growing interest of clinicians and researchers. The Heart Failure 2019 meeting of the Heart Failure Association of the European Society of Cardiology in Athens has therefore created a scientific programme that included four dedicated sessions on the topic along with several additional lectures. The major points that were discussed at the congress included the implementation and delivery of a cardio‐oncology service, the collaboration among cardio‐oncology experts, and the risk stratification, prevention, and early recognition of cardiotoxicity. Furthermore, sessions addressed the numerous different anti‐cancer therapies associated with cardiotoxic effects and provided guidance on how to treat cancer patients who develop cardiovascular disease before, during, and after treatment.
Reference Key
anker2019recentesc Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Anker, Markus S.;Hadzibegovic, Sara;Lena, Alessia;Belenkov, Yury;Bergler‐Klein, Jutta;deBoer, Rudolf A.;Farmakis, Dimitrios;vonHaehling, Stephan;Iakobishvili, Zaza;Maack, Christoph;Pudil, Radek;Skouri, Hadi;Cohen‐Solal, Alain;Tocchetti, Carlo G.;Coats, Andrew J.S.;Seferović, Petar M.;Lyon, Alexander R.;Cardiology, for the Heart Failure Association Cardio‐Oncology Study Group of the European Society of;
Journal ESC heart failure
Year 2019
DOI DOI not found
URL
Keywords

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

No comments yet. Be the first to comment on this article.